Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
FOXP3-T4 in Patients With IPEX Syndrome
NCT07697118Phase 2Not yet recruiting
- Sponsor
- Assistance publique - Hôpitaux de Paris
- Start
- Sep 2026
- Primary completion
- Sep 2028
- Countries
- 1
01
Overview
A Phase 2 trial of FOXP3-T4 in Immune dysregulation, polyendocrinopathy, enteropathy, X-linked syndrome (IPEX), sponsored by Assistance publique - Hôpitaux de Paris. Planned start Sep 2026; status: not yet recruiting.
02
Drugs
FOXP3-T4
03
Conditions
Immune dysregulation, polyendocrinopathy, enteropathy, X-linked syndrome (IPEX)
Beyond the preview
Go deeper on NCT07697118.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07697118.